DoD – ALSRP Program Announcements

April 16, 2018 by

Title: Amyotrophic Lateral Sclerosis Research Program


Therapeutic Idea Award

Therapeutic Development Award

Award Information:

Applications to the Fiscal Year 2018 (FY18) Amyotrophic Lateral Sclerosis Research Program (ALSRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The ALSRP was initiated in 2007 to provide support for research of exceptional scientific merit aimed at the preclinical assessment of therapeutics for amyotrophic lateral sclerosis (ALS). Appropriations for the ALSRP from FY07 through FY17 totaled $69.4 million (M). The FY18 appropriation is $10M.

The Therapeutic Development Award supports research ranging from validation of therapeutic leads to U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven.

The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Projects that focus primarily on investigating the pathophysiology of ALS are not within the scope of this Program Announcement/Funding Opportunity. Development and/or modification of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment are of interest.

Applicants with limited ALS experience are strongly encouraged to collaborate with those having substantial expertise in ALS research and/or ALS model systems.



• Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), June 22, 2018

Invitation to Submit an Application: August 2018

Application Submission Deadline: 11:59 p.m. ET, October 11, 2018

End of Application Verification Period: 5:00 p.m. ET, October 16, 2018

Peer Review: December 2018

For More Information: Detailed descriptions of the funding opportunity, evaluation criteria, and submission requirements can be found in the Program Announcements. The Program Announcements are available electronically for downloading from the website (, the CDMRP website ( and the electronic Biomedical Research Application Portal (eBRAP) ( All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website (



Filed Under: Funding Opportunities